Needham & Company LLC reiterated their buy rating on shares of Cryoport (NASDAQ:CYRX - Free Report) in a report issued on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a $11.00 target price on the stock.
A number of other equities analysts have also recently commented on CYRX. Roth Mkm reissued a "buy" rating and set a $15.00 price target on shares of Cryoport in a report on Tuesday, April 1st. UBS Group boosted their target price on shares of Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Finally, Guggenheim reiterated a "buy" rating and set a $10.00 price target on shares of Cryoport in a report on Wednesday, April 16th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $11.67.
Read Our Latest Stock Report on Cryoport
Cryoport Stock Performance
Cryoport stock traded down $0.03 during midday trading on Wednesday, reaching $5.52. 358,425 shares of the company's stock were exchanged, compared to its average volume of 543,855. Cryoport has a 52 week low of $4.58 and a 52 week high of $17.41. The firm has a market cap of $275.50 million, a price-to-earnings ratio of -1.63 and a beta of 1.81. The stock's 50-day simple moving average is $5.99 and its 200 day simple moving average is $7.00. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.
Cryoport (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same quarter last year, the company posted ($0.29) EPS. On average, analysts expect that Cryoport will post -0.99 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, CEO Jerrell Shelton sold 4,620 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. The trade was a 0.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 19,830 shares of company stock worth $118,353. 10.10% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of CYRX. Rhumbline Advisers grew its holdings in Cryoport by 23.8% in the first quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock worth $476,000 after purchasing an additional 15,036 shares during the last quarter. GAMMA Investing LLC grew its stake in Cryoport by 4,434.6% in the 1st quarter. GAMMA Investing LLC now owns 14,556 shares of the company's stock valued at $89,000 after acquiring an additional 14,235 shares during the period. PharVision Advisers LLC purchased a new stake in Cryoport during the 4th quarter worth approximately $259,000. Squarepoint Ops LLC raised its position in shares of Cryoport by 208.4% in the fourth quarter. Squarepoint Ops LLC now owns 36,499 shares of the company's stock valued at $284,000 after buying an additional 24,665 shares during the last quarter. Finally, State of Wyoming grew its stake in Cryoport by 170.2% during the 4th quarter. State of Wyoming now owns 32,426 shares of the company's stock valued at $252,000 after acquiring an additional 20,427 shares in the last quarter. Institutional investors own 92.90% of the company's stock.
Cryoport Company Profile
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
See Also
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
